Patents by Inventor Ayako Moritomo
Ayako Moritomo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9266840Abstract: To provide a compound useful as an active ingredient of a pharmaceutical composition for treating 11?-hydroxysteroid dehydrogenase type 1-related diseases such as dementia, schizophrenia, depression, pain (particularly, neuropathic pain or fibromyalgia), diabetes (particularly, type II diabetes mellitus), insulin resistance and the like. [Means for Solution] A bicyclic heterocyclic compound (the bicyclic heterocycle is formed when a cyclohexane ring is fused with a 5- to 6-membered monocyclic heterocycle that has only a nitrogen atom as a hetero atom) substituted with an acylamino group such as a (hetero)aroylamino group or the like or a pharmaceutically acceptable salt thereof was found to have an excellent selective inhibitory action against 11?-HSD1.Type: GrantFiled: October 17, 2012Date of Patent: February 23, 2016Assignee: ASTELLAS PHARMA INC.Inventors: Shimpei Kawakami, Minoru Sakurai, Noriyuki Kawano, Takayuki Suzuki, Nobuyuki Shiraishi, Wataru Hamaguchi, Ryuichi Sekioka, Hiroyuki Moritomo, Ayako Moritomo
-
Patent number: 8076348Abstract: [Problem] To provide a compound which can be used in the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in the treatment of irritable bowel syndrome (IBS) and/or prevention of migraine. [Means for Resolution] It was found that an acylguanidine derivative having a tricyclic structure or a pharmaceutically acceptable salt thereof has a strong antagonism to 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having antagonism to both of the receptors showed superior pharmacological action in comparison with the case of the single use of an antagonist selective for either one of the receptors. Based on the above, the compound of the present invention is useful in preventing and/or treating diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in treating irritable bowel syndrome (IBS) and/or preventing migraine.Type: GrantFiled: August 7, 2006Date of Patent: December 13, 2011Assignee: Astellas Pharma Inc.Inventors: Hiroyoshi Yamada, Hirotsune Itahana, Ayako Moritomo, Takaho Matsuzawa, Eisuke Nozawa, Shinobu Akuzawa, Koichiro Harada
-
Publication number: 20110082133Abstract: [Problems] A useful compound which can be used as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease is provided. [Means for Solution] The present inventors have conducted extensive studies on EP4 receptor agonists, and as a result, have found that a novel pyridone compound, in which a group having an acidic group is substituted at the 1-position of the pyridone ring, the 6-position is bonded with an aromatic ring group via a linking part, and the linking part contains a nitrogen atom, has an excellent EP4 receptor agonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor agonistic action, it is useful as a pharmaceutical, in particular, as an agent for treating peripheral arterial occlusive disease.Type: ApplicationFiled: June 16, 2009Publication date: April 7, 2011Inventors: Takashi Kamikubo, Masanori Miura, Takao Okuda, Keisuke Maki, Fukushi Hirayama, Ayako Moritomo, Yuriko Komiya, Keisuke Matsuura, Ryotaro Ibuka
-
Publication number: 20100168096Abstract: [Problem] To provide a compound which can be used in the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in the treatment of irritable bowel syndrome (IBS) and/or prevention of migraine. [Means for Resolution] It was found that an acylguanidine derivative having a tricyclic structure or a pharmaceutically acceptable salt thereof has a strong antagonism to 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having antagonism to both of the receptors showed superior pharmacological action in comparison with the case of the single use of an antagonist selective for either one of the receptors. Based on the above, the compound of the present invention is useful in preventing and/or treating diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in treating irritable bowel syndrome (IBS) and/or preventing migraine.Type: ApplicationFiled: August 7, 2006Publication date: July 1, 2010Inventors: Hiroyoshi Yamada, Hirotsune Itahana, Ayako Moritomo, Takaho Matsuzawa, Eisuke Nozawa, Shinobu Akuzawa, Koichiro Harada
-
Patent number: 7642354Abstract: The present invention provides a genus of polycyclic pyrazines of formula (I): wherein A and B are independently substituted or unsubstituted 5- or 6- membered heterocycloalkyl, or substituted or unsubstituted 5- or 6- membered heteroaryl, W1 is W2is —CH?, —NH—, —N?, —S—, or —O—; Z1 is Z2 is —CH?, —NH—, —N?, —S—, or —O—; Y is a bond, —CH?N—NH—, —NH—CH2, or —NR5—; s and t are independently integers from 1 to 4; and the substituents R1, R2A, R2B and R3 are as defined in the specification for compounds of formula (I). The polycyclic pyrazine compounds are useful as modulators of potassium ion channels in both therapeutic and diagnostic methods.Type: GrantFiled: April 13, 2005Date of Patent: January 5, 2010Assignee: Icagen, Inc.Inventors: Xiaodong Wang, Kerry Leigh Spear, Alan Bradley Fulp, Darrick Seconi, Takeshi Suzuki, Takahiro Ishii, Ayako Moritomo
-
Patent number: 7560464Abstract: The present invention provides a genus of polycyclic pyrimidines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.Type: GrantFiled: April 13, 2005Date of Patent: July 14, 2009Assignee: Icagen, Inc.Inventors: Xiaodong Wang, Kerry Leigh Spear, Alan Bradley Fulp, Darrick Seconi, Takeshi Suzuki, Takahiro Ishii, Ayako Moritomo
-
Publication number: 20080200551Abstract: This invention relates to a novel fluorene derivative having a characteristic structure in which guanidino group or the like functional group is linked to the fluorene structure via carbonyl group, or a salt thereof. The compound of the invention has an advantage in that it has high affinity for serotonin receptor subtypes, particularly for 5-HT2B receptor and 5-HT7 receptor, and shows excellent pharmacological effects in comparison with the conventional compounds which have only one of the antagonistic activities of 5-HT2B receptor and 5-HT7 receptor, this is useful as a prophylactic antimigraine agent having high safety and excellent effect.Type: ApplicationFiled: February 17, 2005Publication date: August 21, 2008Inventors: Hiroyoshi Yamada, Hirotsune Itahana, Ayako Moritomo, Takaho Matsuzawa, Koichiro Harada, Jiro Fujiyasu, Yuji Koga, Makoto Oku, Toshio Okazaki, Shinobu Akuzawa, Toshihiro Watanabe
-
Publication number: 20080108600Abstract: The present invention provides a genus of polycyclic pyridines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.Type: ApplicationFiled: April 13, 2005Publication date: May 8, 2008Applicants: Icagen, Inc., Astellas Parma Inc.Inventors: Xiaodong Wang, Kerry L. Spear, Alan B. Fulp, Darrick Seconi, Takeshi Suzuki, Takahiro Ishii, Ayako Moritomo, Hideki Kubota, Jun-ichi Kazami
-
Publication number: 20050267089Abstract: The present invention provides a genus of polycyclic pyrimidines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.Type: ApplicationFiled: April 13, 2005Publication date: December 1, 2005Applicants: ICAgen, Inc., Astellas Pharma Inc.Inventors: Xiaodong Wang, Kerry Spear, Alan Fulp, Darrick Seconi, Takeshi Suzuki, Takahiro Ishii, Ayako Moritomo
-
Publication number: 20050239800Abstract: The present invention provides a genus of polycyclic pyrazines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.Type: ApplicationFiled: April 13, 2005Publication date: October 27, 2005Applicants: ICAgen, Inc., Astellas Pharma Inc.Inventors: Xiaodong Wang, Kerry Spear, Alan Fulp, Darrick Seconi, Takeshi Suzuki, Takahiro Ishii, Ayako Moritomo
-
Publication number: 20050227989Abstract: The present invention provides a genus of polycyclic thiazoles that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.Type: ApplicationFiled: April 13, 2005Publication date: October 13, 2005Applicants: ICAgen, Inc., Astellas Pharma Inc.Inventors: Xiaodong Wang, Kerry Spear, Alan Fulp, Darrick Seconi, Takeshi Suzuki, Takahiro Ishii, Ayako Moritomo, Hideki Kubota